Dangerous Drug: Enoxaparin(en ocks’ a par in)
Lovenox
PREGNANCY CATEGORY B
Drug Classes
Antithrombotic
Low–molecular-weight heparin
Therapeutic Actions
Low–molecular-weight heparin that inhibits thrombus and clot formation by blocking factor Xa, factor IIa, preventing the formation of clots.
Indications
Prevention of DVT, which may lead to pulmonary embolism following hip replacement, knee replacement surgery, abdominal surgery
Prevention of ischemic complications of unstable angina and non–Q-wave MI
Treatment of DVT, pulmonary embolus with warfarin
Prevention of DVT in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illnesses
Treatment of acute ST-segment elevation MI, managed medically or with subsequent percutaneous coronary intervention
Unlabeled uses: Venous thromboembolism prevention in cancer patients with central venous catheters; DVT prevention in general surgery or gynecologic surgery; prevention of exercise-induced bronchoconstriction
Contraindications and Cautions
Contraindicated with hypersensitivity to enoxaparin, heparin, pork products; severe thrombocytopenia; uncontrolled bleeding.
Use cautiously with pregnancy or lactation, history of GI bleed, spinal tap, spinal/epidural anesthesia.
Available Forms
Injection—30 mg/0.3 mL; 40 mg/0.4 mL; 60 mg/0.6 mL; 80 mg/0.8 mL; 100 mg/mL; 120 mg/0.8 mL; 150 mg/mL; 300 mg/3 mL
Dosages
Adults
DVT prophylaxis after hip or knee replacement surgery: 30 mg subcutaneously bid with initial dose 12–24 hr after surgery. Continue throughout the postoperative period for 7–10 days; or 40 mg daily subcutaneously for up to 14 days may be used.
Patients undergoing abdominal surgery: 40 mg/day subcutaneously begun within 2 hr preoperatively and continued for 7–10 days.
Outpatient DVT treatment: 1 mg/kg subcutaneously every 12 hr.
Inpatient DVT treatment: 1.5 mg/kg subcutaneously once daily or 1 mg/kg every 12 hr.
Unstable angina and non–Q-wave MI: 1 mg/kg subcutaneously every 12 hr for 2–8 days.
Prevention of DVT in high-risk medical patients: 40 mg/day subcutaneously for 6–11 days; has been used up to 14 days.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
